Intellia Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Intellia Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2016 to Q3 2024.
  • Intellia Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $39.6M, a 12.1% increase year-over-year.
  • Intellia Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $150M, a 21.1% increase year-over-year.
  • Intellia Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $134M, a 46.7% increase from 2022.
  • Intellia Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $91.4M, a 94.4% increase from 2021.
  • Intellia Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $47M, a 136% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $150M $39.6M +$4.27M +12.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $145M $40.9M +$4.46M +12.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $141M $34.2M +$6.92M +25.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $134M $35M +$10.4M +42.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-22
Q3 2023 $124M $35.4M +$10.1M +40.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $113M $36.4M +$13.3M +57.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $100M $27.3M +$8.76M +47.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $91.4M $24.6M +$10.1M +69.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-22
Q3 2022 $81.3M $25.2M +$9.81M +63.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $71.5M $23.1M +$12.5M +117% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $59.1M $18.5M +$12.1M +188% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $47M $14.6M +$8.98M +161% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-22
Q3 2021 $38M $15.4M +$10M +185% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $28M $10.6M +$5.85M +123% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $22.2M $6.42M +$2.27M +54.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $19.9M $5.58M +$2.57M +85.1% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 $17.3M $5.4M +$2.32M +75.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $15M $4.76M +$360K +8.17% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $14.7M $4.16M -$435K -9.47% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $15.1M $3.02M -$566K -15.8% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 $15.7M $3.08M -$1.38M -30.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $17M $4.4M -$497K -10.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $17.5M $4.59M +$485K +11.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $17M $3.58M -$3.01M -45.7% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-26
Q3 2018 $20.1M $4.46M +$1.21M +37.2% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-31
Q2 2018 $18.9M $4.9M +$2.05M +72% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 $16.8M $4.11M +$1.48M +56.2% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 $15.3M $6.6M Oct 1, 2017 Dec 31, 2017 10-K 2020-02-27
Q3 2017 $3.25M +$1.19M +58% Jul 1, 2017 Sep 30, 2017 10-Q 2018-10-31
Q2 2017 $2.85M +$1.02M +55.4% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-01
Q1 2017 $2.63M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-01
Q3 2016 $2.06M Jul 1, 2016 Sep 30, 2016 10-Q 2017-10-31
Q2 2016 $1.83M Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.